Cargando…
Update on Retinal Drug Toxicities
PURPOSE OF REVIEW: This review aims to provide an update on the clinical presentations and diagnostic findings of drug-induced retinal toxicities. RECENT FINDINGS: Several newly FDA-approved medications have been associated with acute retinal toxicities, including brolucizumab, MEK inhibitors, ulixe...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688906/ https://www.ncbi.nlm.nih.gov/pubmed/34956737 http://dx.doi.org/10.1007/s40135-021-00277-x |
_version_ | 1784618444682952704 |
---|---|
author | Hsu, S. Tammy Ponugoti, Arathi Deaner, Jordan D. Vajzovic, Lejla |
author_facet | Hsu, S. Tammy Ponugoti, Arathi Deaner, Jordan D. Vajzovic, Lejla |
author_sort | Hsu, S. Tammy |
collection | PubMed |
description | PURPOSE OF REVIEW: This review aims to provide an update on the clinical presentations and diagnostic findings of drug-induced retinal toxicities. RECENT FINDINGS: Several newly FDA-approved medications have been associated with acute retinal toxicities, including brolucizumab, MEK inhibitors, ulixertinib, and FGFR inhibitors. Additionally, as previously believed-to-be well-tolerated medications, such as pentosan sulfate sodium, anti-retroviral therapies, and certain intraoperative ocular medications, are used more frequently or for longer periods of time, associated toxic retinopathies and inflammatory reactions have been reported. Finally, advances in ocular imaging have revealed novel findings in hydroxychloroquine and tamoxifen maculopathies. SUMMARY: Discovery of new medications, increased frequency of use, and longer-term use have led to increased reports of retinal toxicities. Advances in retinal imaging have allowed for earlier detection of subclinical changes associated with these medications, which may help prevent progression of disease. However, more research is needed to determine the point at which vision loss becomes irreversible. Risks and benefits must be assessed prior to discontinuation of the offending, but potentially lifesaving, therapy. |
format | Online Article Text |
id | pubmed-8688906 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-86889062021-12-21 Update on Retinal Drug Toxicities Hsu, S. Tammy Ponugoti, Arathi Deaner, Jordan D. Vajzovic, Lejla Curr Ophthalmol Rep Retina (R Goldhardt, Section Editor) PURPOSE OF REVIEW: This review aims to provide an update on the clinical presentations and diagnostic findings of drug-induced retinal toxicities. RECENT FINDINGS: Several newly FDA-approved medications have been associated with acute retinal toxicities, including brolucizumab, MEK inhibitors, ulixertinib, and FGFR inhibitors. Additionally, as previously believed-to-be well-tolerated medications, such as pentosan sulfate sodium, anti-retroviral therapies, and certain intraoperative ocular medications, are used more frequently or for longer periods of time, associated toxic retinopathies and inflammatory reactions have been reported. Finally, advances in ocular imaging have revealed novel findings in hydroxychloroquine and tamoxifen maculopathies. SUMMARY: Discovery of new medications, increased frequency of use, and longer-term use have led to increased reports of retinal toxicities. Advances in retinal imaging have allowed for earlier detection of subclinical changes associated with these medications, which may help prevent progression of disease. However, more research is needed to determine the point at which vision loss becomes irreversible. Risks and benefits must be assessed prior to discontinuation of the offending, but potentially lifesaving, therapy. Springer US 2021-12-21 2021 /pmc/articles/PMC8688906/ /pubmed/34956737 http://dx.doi.org/10.1007/s40135-021-00277-x Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Retina (R Goldhardt, Section Editor) Hsu, S. Tammy Ponugoti, Arathi Deaner, Jordan D. Vajzovic, Lejla Update on Retinal Drug Toxicities |
title | Update on Retinal Drug Toxicities |
title_full | Update on Retinal Drug Toxicities |
title_fullStr | Update on Retinal Drug Toxicities |
title_full_unstemmed | Update on Retinal Drug Toxicities |
title_short | Update on Retinal Drug Toxicities |
title_sort | update on retinal drug toxicities |
topic | Retina (R Goldhardt, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688906/ https://www.ncbi.nlm.nih.gov/pubmed/34956737 http://dx.doi.org/10.1007/s40135-021-00277-x |
work_keys_str_mv | AT hsustammy updateonretinaldrugtoxicities AT ponugotiarathi updateonretinaldrugtoxicities AT deanerjordand updateonretinaldrugtoxicities AT vajzoviclejla updateonretinaldrugtoxicities |